JP4409680B2 - 三環性縮合イミダゾール誘導体 - Google Patents

三環性縮合イミダゾール誘導体 Download PDF

Info

Publication number
JP4409680B2
JP4409680B2 JP29521499A JP29521499A JP4409680B2 JP 4409680 B2 JP4409680 B2 JP 4409680B2 JP 29521499 A JP29521499 A JP 29521499A JP 29521499 A JP29521499 A JP 29521499A JP 4409680 B2 JP4409680 B2 JP 4409680B2
Authority
JP
Japan
Prior art keywords
compound
mmol
yield
nmr
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP29521499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001114780A (ja
JP2001114780A5 (https=
Inventor
▲隆▼ 八重樫
裕之 西山
利幸 逸見
誠吾 沢田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP29521499A priority Critical patent/JP4409680B2/ja
Priority to PCT/JP2000/007201 priority patent/WO2001029038A1/ja
Priority to AU79470/00A priority patent/AU7947000A/en
Publication of JP2001114780A publication Critical patent/JP2001114780A/ja
Publication of JP2001114780A5 publication Critical patent/JP2001114780A5/ja
Application granted granted Critical
Publication of JP4409680B2 publication Critical patent/JP4409680B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP29521499A 1999-10-18 1999-10-18 三環性縮合イミダゾール誘導体 Expired - Fee Related JP4409680B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP29521499A JP4409680B2 (ja) 1999-10-18 1999-10-18 三環性縮合イミダゾール誘導体
PCT/JP2000/007201 WO2001029038A1 (en) 1999-10-18 2000-10-18 Tricyclic fused-imidazole derivatives
AU79470/00A AU7947000A (en) 1999-10-18 2000-10-18 Tricyclic fused-imidazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29521499A JP4409680B2 (ja) 1999-10-18 1999-10-18 三環性縮合イミダゾール誘導体

Publications (3)

Publication Number Publication Date
JP2001114780A JP2001114780A (ja) 2001-04-24
JP2001114780A5 JP2001114780A5 (https=) 2006-03-23
JP4409680B2 true JP4409680B2 (ja) 2010-02-03

Family

ID=17817687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP29521499A Expired - Fee Related JP4409680B2 (ja) 1999-10-18 1999-10-18 三環性縮合イミダゾール誘導体

Country Status (3)

Country Link
JP (1) JP4409680B2 (https=)
AU (1) AU7947000A (https=)
WO (1) WO2001029038A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
WO2013055793A1 (en) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
CN102898425B (zh) * 2012-10-30 2014-10-08 黑龙江八一农垦大学 4,5-二氢咪唑[1,2-a]喹啉衍生物及其应用
JP6523267B2 (ja) * 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422918D0 (en) * 1984-09-11 1984-10-17 May & Baker Ltd Compositions of matter
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
JP2001114780A (ja) 2001-04-24
AU7947000A (en) 2001-04-30
WO2001029038A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
JP4409680B2 (ja) 三環性縮合イミダゾール誘導体
EP1206474B1 (en) Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
RU2269519C2 (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
JP6294277B2 (ja) Ｈｅｃ１活性の調節因子およびそのための方法
TW502025B (en) Pyridazine derivatives having inhibitory activity against interleukin-1β production and pharmaceutical composition containing the same
US20050075375A1 (en) Heterocyclic compounds for treating hepatitis C virus
US20220096450A1 (en) Compounds and Methods for Treating or Preventing Heart Failure
JP2019089856A (ja) アリールエーテルおよびその使用
US11292787B2 (en) Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof
CN102725281A (zh) 作为wtn通路抑制剂的氮杂茂类衍生物
HUP0302508A2 (hu) Piridazinon- és triazinonszármazékok, valamint alkalmazásuk gyógyászati készítmények hatóanyagaiként
JP2013518864A (ja) １，２，４−トリアジン−４−アミン含有誘導体
KR20010099634A (ko) 텔로머라제 저해제 및 그 사용 방법
JPWO2002004427A1 (ja) フェニルピリダジン誘導体及びこれを含有する医薬
JPWO1998046594A1 (ja) ピラゾール誘導体およびそれを含有するｃｏｘ阻害剤
HU198696B (en) Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
CA2977626A1 (en) Substituted pyrimidine compounds as phosphatidylinositol 3-kinase .delta. inhibitor and use thereof
US10738047B2 (en) Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
JP6231195B2 (ja) スルホニルインドール誘導体およびその製造方法
US20200338084A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
CN104211661A (zh) 查尔酮类化合物及其制法和药物用途
KR19980701690A (ko) 엔도텔린 길항제로서의 치환 페닐 화합물
JP2026503618A (ja) Ｓａｒｍ１阻害剤としての置換された１ｈ－ピラゾール－４－カルボキサミド
US20110015395A1 (en) Pyrazole compounds with inhibitory activity against ros kinase
WO2022089219A1 (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091027

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091112

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121120

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121120

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131120

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees